Announcements Trials
Browse Landscape

Phase

Phase 1 123Phase 1/2 79Phase 2 66Phase 3 26Phase NA 13Phase EARLY_PHASE1 4Phase 4 2Phase 2/3 2

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER 12INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Carcinoma, Non-Small-Cell Lung 27Neoplasms 22Breast Neoplasms 20Neoplasm Metastasis 18Colorectal Neoplasms 16Stomach Neoplasms 15Recurrence 15Prostatic Neoplasms 15Carcinoma, Hepatocellular 12Pancreatic Neoplasms 11Ovarian Neoplasms 11Head and Neck Neoplasms 11Squamous Cell Carcinoma of Head and Neck 10Lung Neoplasms 10Myasthenia Gravis 9Melanoma 9Leukemia, Myeloid, Acute 9Urinary Bladder Neoplasms 8Lymphoma, Large B-Cell, Diffuse 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Multiple Myeloma 6Lymphoma, Non-Hodgkin 6Liver Neoplasms 6Cholangiocarcinoma 6Carcinoma, Transitional Cell 6Triple Negative Breast Neoplasms 5Small Cell Lung Carcinoma 5Lymphoma, Follicular 5Leukemia, Myelogenous, Chronic, BCR-ABL Positive 5Leukemia 5

Interventions

navtemadlin; 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid 1Paclitaxel 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × INDUSTRY × Endometrial Neoplasms × Clear all
NCT06321068 2025-08-14

BAT1308 in Combination With Platinum-containing Chemotherapy is Used for the First-line Treatment of Advanced or Recurrent dMMR Endometrial Cancer

Bio-Thera Solutions

Phase 2/3 Terminated
5 enrolled
Gynecologic

Endometrial Neoplasms

NCT05797831 2024-05-02

Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer

Kartos Therapeutics, Inc.

Phase 2/3 Recruiting
268 enrolled
Gynecologic

Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡